Cipla gets EIR from USFDA for Kurkumbh facility
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
Cipla has received EIR from the US health regulator after inspection of Kurkumbh facility in Maharashtra, Photo: Reuters
By PTI
Updated: Mon, Jun 10, 2019
06:38 pm
06:38 pm
New Delhi, PTI
'10 ki Kamai': Should you buy Cipla shares? Expert gives this targetPharma major Cipla Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of Kurkumbh facility in Maharashtra.
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
The company has received the EIR indicating closure of the inspection, it added.
Shares of Cipla closed at Rs 553.70 per scrip on the BSE, up 0.75 per cent from its previous close.
Cipla Q4 net profit jumps over 2-fold to Rs 357.68 cr; to raise up to Rs 6,000 cr
Cipla to launch cinacalcet hydrochloride tablets in US. 
Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018
Cipla recalls 4,800 bottles of anti-HIV tablets from US